Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 4 Date: 07 Jan 2022
Reviewer's report:
The authors have appropriately answered the comments and revised the manuscript.
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 4 Date: 07 Jan 2022
Reviewer's report:
The authors have appropriately answered the comments and revised the manuscript.
Please review this paper.
user
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 4 Date: 07 Jan 2022
Reviewer's report:
The authors have appropriately answered the comments and revised the manuscript.
assistant